Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crenolanib in Relapsed/Refractory FLT3-Mutated AML
NCT01522469Phase 2
Key facts
- Status
- Completed
- Start
- Jul 2012
- Primary completion
- Aug 2014
- Countries
- 1
- Sponsor
- AROG Pharmaceuticals, Inc.
- Modality
- Small Molecules
- Drugs
- crenolanib
- Conditions
- acute myeloid leukemia (AML)
01
Overview
Phase 2, open-label, single-arm trial of crenolanib in acute myeloid leukemia (AML), sponsored by AROG Pharmaceuticals, Inc. Primary endpoint: Overall Response Rate at 1 year. Started Jul 2012; status: completed.
02
Design
1 arm- Study design
- Non-randomizedOpen-label
Crenolanib Besylate
Crenolanib monotherapy
03
Who it enrols
Patients with relapsed/refractory AML and FLT3 activating mutations, ECOG 0-2, and adequate organ function.
04
Endpoints
Primary
Overall Response Rate
Beyond the preview
Go deeper on NCT01522469.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01522469.